Smiths Group Plans a Rebuild as It is Hit by Ailing Medical Arm, Pays £118M Special Dividend

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Smiths Group has seen revenue and profit drop in its medical unit which it failed to sell this summer. The division, alongside Smiths’ slumping explosives detection business, will now be subjected to a groupwide restructuring which chief executive Philip Bowman believes could lead to £50 million in cost savings over the next four years. Smiths’ government work in developed markets has been hit by austerity measures in the wake of the financial crisis, leaving annual pre-tax profit flat at £498 million and revenue up a mere 2% to £3.1 billion.

Help employers find you! Check out all the jobs and post your resume.

Back to news